Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, Chou T, Sano M, Makino H, Igarashi T, Sasaki Y, Imoto S, Ogura M, Morishima Y, Murai H, Okamoto S, Ikeda T, Kasai M, Yokozawa T, Tobinai K. Narabayashi M, et al. Among authors: kasai m. Jpn J Clin Oncol. 1999 Jun;29(6):285-90. doi: 10.1093/jjco/29.6.285. Jpn J Clin Oncol. 1999. PMID: 10418556 Clinical Trial.
Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T, Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K. Itoh K, et al. Among authors: kasai m. Leuk Lymphoma. 2000 Aug;38(5-6):521-32. doi: 10.3109/10428190009059271. Leuk Lymphoma. 2000. PMID: 10953973 Clinical Trial.
Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K; IDEC-C2B8 Study Group. Igarashi T, et al. Among authors: kasai m. Int J Hematol. 2001 Feb;73(2):213-21. doi: 10.1007/BF02981940. Int J Hematol. 2001. PMID: 11372734 Clinical Trial.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan. Igarashi T, et al. Among authors: kasai m. Ann Oncol. 2002 Jun;13(6):928-43. doi: 10.1093/annonc/mdf155. Ann Oncol. 2002. PMID: 12123339 Free article. Clinical Trial.
[A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
Chou T, Ishiguro T, Imajo K, Kawano F, Gondo H, Kasai M, Masuda M, Koike M, Shimazaki C, Hara M, Shinagawa K, Ogawa M, Takaku F, Harada M. Chou T, et al. Among authors: kasai m. Rinsho Ketsueki. 1999 Oct;40(10):1058-67. Rinsho Ketsueki. 1999. PMID: 10565222 Clinical Trial. Japanese.
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M. Tobinai K, et al. Among authors: kasai m. Cancer Sci. 2011 Feb;102(2):432-8. doi: 10.1111/j.1349-7006.2010.01809.x. Epub 2011 Jan 12. Cancer Sci. 2011. PMID: 21205069 Free article. Clinical Trial.
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. Oki Y, et al. Among authors: kasai m. Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14. Cancer Sci. 2012. PMID: 22816487 Free PMC article. Clinical Trial.
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, Ohata J. Ogura M, et al. Among authors: kasai m. Cancer Sci. 2010 Aug;101(8):1840-5. doi: 10.1111/j.1349-7006.2010.01601.x. Epub 2010 Apr 23. Cancer Sci. 2010. PMID: 20491780 Free PMC article. Clinical Trial.
1,269 results